GSK completes Sirtris acquisition
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline acquires Sirtris Pharmaceuticals for approximately $720 million through a cash tender offer and merger of $22.50 per share, the firms state June 6. The buy significantly enhances GSK's "metabolic, neurology, immunology and inflammation research efforts by establishing a presence in the field of sirtuins, a recently discovered class of enzymes that is believed to be involved in the ageing process," according to the London-based firm. Sirtris' lead compound is resveratrol based (1"The Tan Sheet" April 28, 2008, In Brief)....
You may also be interested in...
GSK buys Sirtris
GlaxoSmithKline will acquire Sirtris Pharmaceuticals for approximately $720 million through a cash tender offer of $22.50 per share, which is an 84 percent premium on Sirtris' closing price April 22 - the day the deal was announced. GSK says the acquisition will "significantly enhance its metabolic, neurology, immunology and inflammation research efforts by establishing a presence in the field of sirtuins," a seven-member family of proteins long thought to play a role in the aging process, with "potentially transformative" benefits addressing diseases such as diabetes, muscle wasting and neuron-degeneration. Sirtris' lead compound, the resveratrol formulation SRT501, "significantly" lowered glucose in an oral glucose tolerance test conducted as part of a 28-day Phase 1b clinical study in type 2 diabetes patients, the firm said in January (1"The Tan Sheet" Jan. 14. 2008, In Brief). Sirtris will become part of GSK's Drug Discovery division while operating in Cambridge, Mass., as an autonomous unit. The deal is subject to closing conditions, but the firms expect the tender offer to commence in May and close in the second quarter of 2008...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.